Join the VIRTUAL Challenge
to support diabetes patients
Join the VIRTUAL Challenge
to support diabetes patients
Submit ONE word to the word cloud question below.
Here is how to win the Virtual Challenge.
Country with the highest total word count will win
   Boehringer Ingelheim will donate to winning country's local organization of choice 
Let’s work together to give TIME and POWER to your T2D patients’ lives
Start Empagliflozin (JARDIANCE®) early to realize the CV protection it provides1
What would you like to achieve as early as now?
  • 38 % cv deaths
  • achieve early cv protection
  • achieve good control of hba1c
  • agelessness
  • best qol
  • best quality of life
  • blood sugar control
  • cardiac risk reduction
  • cardio and renal protection
  • cardiorenal protection
  • cardiovascular protection
  • change
  • complications
  • consistent hba1c reduction
  • contr
  • control
  • controlled sugar level
  • cv and kidney protection
  • cv protection
  • cv benefits
  • cv benifits
  • cv death reduction
  • cv protection
  • cv protection with jardiance.
  • cvprotection
  • decrease cardiovascular death
  • decrease cardiovascular risk
  • dwudguhwef
  • early cv protection
  • early protection
  • effective glucose control
  • equilibrium
  • exercise
  • freedom
  • gej;hdoegfewfjrfufduo;
  • glucose control
  • glycemic control
  • good glycemic control
  • good health
  • good sugar control
  • hello123
  • jardiance
  • longevity
  • more
  • normal blood sugar levels
  • normoglycemia
  • power
  • prevention
  • protection
  • protection from cv death
  • qol
  • quality of life
  • reduce cv death risk
  • reduce cvd death
  • reduce hospitalization
  • reduce the risk of cvd death
  • reduced cv death
  • safety
  • stability
  • success
  • sugar control
  • test
  • time
  • travel
  • weight control
  • weight loss
EMPRO-09JULEMPRO-16JUL
Check out how many words are submitted in other countries and 
Participate to Win!
  • ID 317
  • MY 43
  • PH 798
  • SG 61
  • SK 263
  • TH 79
  • VN 907
References
  1. Empagliflozin (JARDIANCE®) [summary product characterestics] Ingelheim am Rhein, Germany: Boehringer Ingelheim International GmbH; 2020.
  2. Zinman B, Wanner C, Lachin J, et al; EMPA-REG OUTCOME® investigators. Empagliflozin (JARDIANCE®), cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373(22):2117-2128.
  3. Wanner C, Inzucchi S, Lachin J, et al; EMPA-REG OUTCOME® investigators. Empagliflozin (JARDIANCE®) and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323-334.
Footnotes
  • ‡ The 38% RRR in CV death was achieved in the overall EMPA-REG OUTCOME® population for the duration of the trial (HR=0.62; 95% Cl:0.49, 0.77; P<0.001).
  • *Incident or worsening nephropathy is defined as progression to macroalbuminuria, doubling of serum creatinine, eGFR of ≤45 mL/min/1.73m2; initiation of renal replacement therapy; death from renal disease. Incident or worsening nephropathy was a prespecified component of the secondary microvascular CV outcome in the EMPA-REG OUTCOME® trial (HR=0.61; 95% Cl: 053, 070; P<0.001) for Empagliflozin (JARDIANCE®) (12.7%) versus placebo (18.8%).